DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and ...